Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Contributed by: PR Newswire

Tags

LUNDBECK-CD-TED-data

More Like This

Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston